Cytotoxic T Lymphocyte Responses to Transgene Product, Not Adeno-Associated Viral Capsid Protein, Limit Transgene Expression in Mice
Authors:
- 1 January 2009
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 20 (1) , 11-20
Abstract
The use of adeno-associated viral (AAV) vectors for gene replacement therapy is currently being explored in several clinical indications. However, reports have suggested that input capsid proteins from AAV-2 vector particles may result in the stimulation of cytotoxic T lymphocyte (CTL) responses that can result in a loss of transduced cells. To explore the impact of anti-AAV CTLs on AAV-mediated transgene expression, both immunocompetent C57BL/6 mice and B cell-deficient μMT mice were immunized against the AAV2 capsid protein (Cap) and were injected intravenously with an AAV-2 vector encoding α-galactosidase (α-Gal). C57BL/6 mice, which developed both CTL and neutralizing antibody responses against Cap, failed to show any detectable α-Gal expression. In contrast, serum α-Gal levels comparable to those of naive mice were observed in μMT mice despite the presence of robust CTL activity against Cap, indicating that preexisting Cap-specific CTLs did not have any effect on the magnitude and duration of transgene expression. The same strategy was used to assess the impact of CTLs against the α-Gal transgene product on AAV-mediated gene delivery and persistence of transgene expression. Preimmunization of μMT mice with an Ad/α-Gal vector induced a robust CTL response to α-Gal. When these mice were injected with AAV2/α-Gal vector, initial levels of α-Gal expression were reduced by more than 1 log and became undetectable by 2 weeks postinjection. Overall, our results indicate that CTLs against the transgene product as opposed to AAV capsid protein are more likely to interfere with AAV transgene expression.Keywords
This publication has 30 references indexed in Scilit:
- Progress and Prospects: Gene Therapy Clinical Trials (Part 2)Gene Therapy, 2007
- Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In VivoJournal of Virology, 2007
- Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced HepatocytesMolecular Therapy, 2007
- Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic TargetsHuman Gene Therapy, 2007
- Recent Developments in the Application of Plasmid DNA-Based Vectors and Small Interfering RNA Therapeutics for CancerHuman Gene Therapy, 2006
- Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID miceBlood, 2006
- Immune responses to gene therapy vectors: influence on vector function and effector mechanismsGene Therapy, 2004
- Immune responses to adeno-associated virus and its recombinant vectorsGene Therapy, 2003
- Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of AdministrationClinical Immunology, 1999
- A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain geneNature, 1991